<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E94047FA-2B64-4B5E-BF12-B480D820DA31"><gtr:id>E94047FA-2B64-4B5E-BF12-B480D820DA31</gtr:id><gtr:name>Beijing Genomics Institute (BGI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E589D68-A73C-42BB-892C-BC508C7B60CA"><gtr:id>5E589D68-A73C-42BB-892C-BC508C7B60CA</gtr:id><gtr:name>University of Hertfordshire</gtr:name><gtr:address><gtr:line1>Hatfield Campus</gtr:line1><gtr:line2>College Lane</gtr:line2><gtr:line4>Hatfield</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>AL10 9AB</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/195BC08F-39A5-40F6-93B8-40463AA9A2AF"><gtr:id>195BC08F-39A5-40F6-93B8-40463AA9A2AF</gtr:id><gtr:name>Protagen AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C6D419CE-BBD7-4220-BFEC-AB98637B78E2"><gtr:id>C6D419CE-BBD7-4220-BFEC-AB98637B78E2</gtr:id><gtr:name>Pharmatics Limited</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A9BE6F2A-7F69-4499-8DCC-04808C493698"><gtr:id>A9BE6F2A-7F69-4499-8DCC-04808C493698</gtr:id><gtr:name>Qiagen</gtr:name><gtr:address><gtr:line1>QIAGEN GmbH</gtr:line1><gtr:line2>QIAGEN Strasse 1</gtr:line2><gtr:postCode>40724</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CFA3CCE-D7B5-4E91-8299-47E773A16C97"><gtr:id>2CFA3CCE-D7B5-4E91-8299-47E773A16C97</gtr:id><gtr:name>Abbvie</gtr:name><gtr:address><gtr:line1>1 North Waukegan Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAA77269-CB2A-42CE-81EF-0E594636D7A2"><gtr:id>FAA77269-CB2A-42CE-81EF-0E594636D7A2</gtr:id><gtr:name>Avacta Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AA7CF37A-1A3C-4DC6-8488-4445B285ACA2"><gtr:id>AA7CF37A-1A3C-4DC6-8488-4445B285ACA2</gtr:id><gtr:name>Genentech</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>William Harvey Research Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E94047FA-2B64-4B5E-BF12-B480D820DA31"><gtr:id>E94047FA-2B64-4B5E-BF12-B480D820DA31</gtr:id><gtr:name>Beijing Genomics Institute (BGI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E589D68-A73C-42BB-892C-BC508C7B60CA"><gtr:id>5E589D68-A73C-42BB-892C-BC508C7B60CA</gtr:id><gtr:name>University of Hertfordshire</gtr:name><gtr:address><gtr:line1>Hatfield Campus</gtr:line1><gtr:line2>College Lane</gtr:line2><gtr:line4>Hatfield</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>AL10 9AB</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/195BC08F-39A5-40F6-93B8-40463AA9A2AF"><gtr:id>195BC08F-39A5-40F6-93B8-40463AA9A2AF</gtr:id><gtr:name>Protagen AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C6D419CE-BBD7-4220-BFEC-AB98637B78E2"><gtr:id>C6D419CE-BBD7-4220-BFEC-AB98637B78E2</gtr:id><gtr:name>Pharmatics Limited</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A9BE6F2A-7F69-4499-8DCC-04808C493698"><gtr:id>A9BE6F2A-7F69-4499-8DCC-04808C493698</gtr:id><gtr:name>Qiagen</gtr:name><gtr:address><gtr:line1>QIAGEN GmbH</gtr:line1><gtr:line2>QIAGEN Strasse 1</gtr:line2><gtr:postCode>40724</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CFA3CCE-D7B5-4E91-8299-47E773A16C97"><gtr:id>2CFA3CCE-D7B5-4E91-8299-47E773A16C97</gtr:id><gtr:name>Abbvie</gtr:name><gtr:address><gtr:line1>1 North Waukegan Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAA77269-CB2A-42CE-81EF-0E594636D7A2"><gtr:id>FAA77269-CB2A-42CE-81EF-0E594636D7A2</gtr:id><gtr:name>Avacta Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AA7CF37A-1A3C-4DC6-8488-4445B285ACA2"><gtr:id>AA7CF37A-1A3C-4DC6-8488-4445B285ACA2</gtr:id><gtr:name>Genentech</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A6F9F7F9-48F8-49AA-AF79-FD9895BF0C67"><gtr:id>A6F9F7F9-48F8-49AA-AF79-FD9895BF0C67</gtr:id><gtr:firstName>Jennifer</gtr:firstName><gtr:surname>Barrett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6A7AEE45-7C3C-46BC-B0FD-2BD6B17DBBB9"><gtr:id>6A7AEE45-7C3C-46BC-B0FD-2BD6B17DBBB9</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Paul</gtr:otherNames><gtr:surname>Cope</gtr:surname><gtr:orcidId>0000-0001-6735-5496</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8B655D32-2D40-4464-8752-DD206A7BC0F4"><gtr:id>8B655D32-2D40-4464-8752-DD206A7BC0F4</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Matthew</gtr:otherNames><gtr:surname>McKeigue</gtr:surname><gtr:orcidId>0000-0002-5217-1034</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/81E455DE-3436-49A5-B2A8-B6ABDCB8D837"><gtr:id>81E455DE-3436-49A5-B2A8-B6ABDCB8D837</gtr:id><gtr:firstName>Costantino</gtr:firstName><gtr:surname>Pitzalis</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/16B653E2-0DEA-4EC3-BEB0-B755754726BD"><gtr:id>16B653E2-0DEA-4EC3-BEB0-B755754726BD</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Buckley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC1F25AE-D6DB-4548-8C27-8499AC6C5B8C"><gtr:id>DC1F25AE-D6DB-4548-8C27-8499AC6C5B8C</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Gerard</gtr:otherNames><gtr:surname>Wilson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EF2AB7DE-973A-4C76-9CB4-4DC90DB48CAA"><gtr:id>EF2AB7DE-973A-4C76-9CB4-4DC90DB48CAA</gtr:id><gtr:firstName>Ann Wendy</gtr:firstName><gtr:surname>Morgan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6E8E3B1A-303A-414A-8591-9674F02A9B97"><gtr:id>6E8E3B1A-303A-414A-8591-9674F02A9B97</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Worthington</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3A7E85FB-9050-4F4C-976A-D4E0CD6660B7"><gtr:id>3A7E85FB-9050-4F4C-976A-D4E0CD6660B7</gtr:id><gtr:firstName>Kimme</gtr:firstName><gtr:surname>Hyrich</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/57A37958-62F0-4123-94F1-B401A3343848"><gtr:id>57A37958-62F0-4123-94F1-B401A3343848</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Dudley</gtr:otherNames><gtr:surname>Isaacs</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F2C9D75C-2BAC-4470-B9D7-445E2472DCA4"><gtr:id>F2C9D75C-2BAC-4470-B9D7-445E2472DCA4</gtr:id><gtr:firstName>Karim</gtr:firstName><gtr:surname>Raza</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5B3542A5-6221-48C5-96DE-AB051B608C89"><gtr:id>5B3542A5-6221-48C5-96DE-AB051B608C89</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:surname>Young</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EEE5331C-7D11-4578-BAC5-788C990A6C47"><gtr:id>EEE5331C-7D11-4578-BAC5-788C990A6C47</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>McInnes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/79AE2828-BA20-497E-8662-139D8EF45415"><gtr:id>79AE2828-BA20-497E-8662-139D8EF45415</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:surname>Barton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DB9EFB9A-C5B8-463F-966C-E407D0CD4D37"><gtr:id>DB9EFB9A-C5B8-463F-966C-E407D0CD4D37</gtr:id><gtr:firstName>Ernest</gtr:firstName><gtr:surname>Choy</gtr:surname><gtr:orcidId>0000-0003-4459-8609</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/361048BA-EE7A-4D91-95C8-CBA3DFB38F7F"><gtr:id>361048BA-EE7A-4D91-95C8-CBA3DFB38F7F</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Sasieni</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/66889F1D-4B16-4D0C-B5C5-3B14F02A8018"><gtr:id>66889F1D-4B16-4D0C-B5C5-3B14F02A8018</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Barnes</gtr:surname><gtr:orcidId>0000-0001-9097-7381</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0D1BB1B6-A7EC-4CE0-942B-734C4A958A34"><gtr:id>0D1BB1B6-A7EC-4CE0-942B-734C4A958A34</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C2EFBEBC-ABA1-4F35-8546-22F2100F49DC"><gtr:id>C2EFBEBC-ABA1-4F35-8546-22F2100F49DC</gtr:id><gtr:firstName>Heather</gtr:firstName><gtr:surname>Cordell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/005217C7-CBD3-44AD-9F35-6949D9804F4A"><gtr:id>005217C7-CBD3-44AD-9F35-6949D9804F4A</gtr:id><gtr:firstName>Deborah</gtr:firstName><gtr:otherNames>Pauline</gtr:otherNames><gtr:surname>Symmons</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/44B4E2FB-3F1F-471C-BF9F-BF1C27C7464E"><gtr:id>44B4E2FB-3F1F-471C-BF9F-BF1C27C7464E</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Randolph</gtr:otherNames><gtr:surname>Ehrenstein</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK015346%2F1"><gtr:id>5E04CC61-362E-4130-879A-3B80268ED043</gtr:id><gtr:title>Maximising Therapeutic Utility for Rheumatoid Arthritis using genetic and genomic tissue responses to stratify medicines.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K015346/1</gtr:grantReference><gtr:abstractText>Rheumatoid arthritis (RA) is a disease in which inflammation of joints can cause pain, stiffness, lasting damage and disability. It affects an estimated 500,000 people in the UK and has important impacts on their lives. For example, within 5 years of diseases onset, 33% people are unable to remain in full-time work. 
There have been dramatic advances in treatment of RA in recent years. First, patients are treated with drugs as soon as they are diagnosed with RA and the dose is increased quickly to try and suppress all joint inflammation. The most common drug used is called methotrexate (MTX). Second, those people who fail to respond to MTX can be given a biologic drug, so-called because they inhibit a biological pathway involved in inflammation. There are a number of biologic drugs that can be used; most commonly, anti-tumour necrosis factor (TNF) therapies are used as the first choice biologic. Patients who fail to respond to those are then switched to try a biologic drug that acts by removing B cells from the circulation (rituximab, RTX). More recently, a biologic drug that acts by blocking another inflammatory pathway, the IL6 pathway, has been recommended for use (tocilizumab, TOC). Whilst each of these drugs has been proven to control inflammation and slow or prevent lasting joint damage, they don't work for every patient. Thus, 45% patients fail to respond to MTX whilst 30-40% fail to respond to each of the biologic drugs. At the moment, we have no means of predicting which patients will respond best to which drug and so the drugs are prescribed on a 'trial and error' basis. However, we know that the longer it takes to find an effective therapy, the more joint damage accumulates and the worse the long-term outlook is for patients. Therefore, the aim of this study is to identify predictors of response to MTX, anti-TNF, RTX and TOC so that patients with RA can be given the drug that they are most likely to respond to, as soon as they are diagnosed. 
The response predictors may be changes in DNA, proteins or other molecules and these changes may be detectable in blood samples or in the joint tissues that are inflamed. In this program of work, we plan a comprehensive series of experiments to investigate this. We will study both tissue samples taken from the joints of patients with RA as well as blood samples collected from large numbers of RA patients treated with each of the 4 drugs to be investigated. We will study genetic changes, protein levels and other molecules. We will combine the information obtained to test whether combinations of markers predict response better than studying one marker at a time. We already have evidence to suggest that the number of B cells in the inflamed joint tissue can predict whether patients are likely to respond well to the B cell depleting therapy, RTX. Therefore, we also plan to test how well this works in practice by performing a randomized clinical trial whereby patients will be randomly assigned to receive RTX or another biologic therapy based on the level of B cell infiltration seen in their joint tissue.
The outcome of this study will be the identification of blood or tissue markers that help to target the right treatments to the right patients with RA. This is particularly important because the biologic drugs are very expensive (&amp;pound;8-10,000 per patient per year). Crucially, as the annual cost of biologics to the NHS is ~&amp;pound;160 million, the identification of the 30-40% of non-responders prior to &amp;quot;blind&amp;quot; therapy would potentially save &amp;pound;13-18 million annually because approximately 4-5,000 patients start anti-TNF therapy each year in the UK.</gtr:abstractText><gtr:technicalSummary>Research objectives: Two parallel workstrands (WS) will investigate synovial tissue and blood correlates (WS.1) and large scale blood based screening (WS.2) to identify biomarkers of response to four drugs which from the main steps in treatment escalation in rheumatoid arthritis (RA): methotrexate (MTX), anti-tumour necrosis factor (anti-TNF) and rituximab (RTX) and tocilizumab (TOC).
Methodology and experimental design: WS.1: We shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 &amp;amp; 6 months biopsy) in the world &amp;amp; clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (&amp;quot;pathotypes&amp;quot;) will enrich for response to existing biologic therapies. WS.2: we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX- and 1,200 RTX-treated subjects. 
Proposed techniques and approaches: The two WSs are fully integrated through &amp;quot;multi-omic&amp;quot; approaches that constitute cross-cutting themes (CTs) incorporating genetic, genomic, transcriptomic, and proteomic studies. Both WSs converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics to identify individual or, more likely, a combination of factors that predict treatment response to each of the four drugs. A preliminary health economic assessment of identified biomarkers will also be undertaken. 
Exploitation of results: In collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit</gtr:technicalSummary><gtr:potentialImpactText>Commercial beneficiaries:
Immediate commercial beneficiaries are the commercial parties of this consortium including large pharma e.g. Amgen, Pfizer, UCB Pharma, Pfizer, diagnostics companies e.g Qiagen and small biotech e.g. Activiomics.
 
We have developed a strong industry engagement network that has led to a major Industry response with firm intellectual, in-kind and financial contributions from 10 commercial partners (see MICA forms). Industrial partners have been selected to provide expertise in their areas of research, development and commercialisation, as global leaders in the field of therapeutic and (companion) diagnostic development.
 
Testing of the biomarker will have to be standardized before widespread introduction into clinical practice. Thus commercial diagnostics companies will benefit from development of a point-of-care companion diagnostic or delivery of a clinical test in a CLIA lab. Our industry collaborators will provide a means to facilitate direct engagement with large pharmaceutical companies and SMEs.
 
Policy makers: Given the expense of biologic drugs and their significant failure rate, policy makers will benefit from this research. Thus our data will contribute to assessments by the National Institute of Health and Clinical Excellence (NICE) to optimize and rationalize treatment for RA.
 
Patient and public beneficiaries: Ultimately, patients should benefit from this research because it will enable them to be treated earlier in their care pathway with a drug that is most likely to induce remission of symptoms and least likely to induce serious adverse events. This will have downstream consequences for employment and care providers thus having a wider social and economic impact.</gtr:potentialImpactText><gtr:fund><gtr:end>2021-03-02</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-03-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>5089889</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Botnar Research Centre</gtr:department><gtr:description>MATURA Consortium</gtr:description><gtr:id>16B227E8-8562-4658-9DF4-257743F0DF1B</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-3</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hertfordshire</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MATURA Consortium</gtr:description><gtr:id>6E214BE4-2D0D-49F9-A6F0-61BB1D9182C4</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-6</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Newcastle</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>MATURA Consortium</gtr:description><gtr:id>65CE4802-FA3A-4535-9D57-ECA743CF87DE</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-9</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genentech</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Genentech/Roche</gtr:description><gtr:id>BA1A0B44-9F89-4B73-8E73-DE91493E077D</gtr:id><gtr:impact>Genentech are providing the study drugs (tocilizumab and rituximab), and will
provide expertise to help design the study and study protocol and will take part in analysis
of samples (including serum, whole blood RNA and Synovial biopsy RNA) that could lead to
potential companion diagnostics.</gtr:impact><gtr:outcomeId>54648c6f3133f2.90800154-1</gtr:outcomeId><gtr:partnerContribution>Research collaboration, knowledge transfer and data sharing</gtr:partnerContribution><gtr:piContribution>Research collaboration and data sharing.The collaboration will enable the proposed study to be undertaken by providing drug that will
allow for comparison of response within the proposed subsets of rheumatoid arthritis. In addition, the collaboration between the consortium and industry in the design of the trial will lead to an optimized study protocol. Lastly, analysis of the
samples will enable exploratory biomarker research to identify new, non-invasive, biomarkers and potential companion diagnostics.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MATURA Consortium</gtr:description><gtr:id>F1B244C4-C9FA-4539-B904-44FFCA948149</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-11</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MATURA Consortium</gtr:description><gtr:id>BB4AB6A1-592B-4158-8208-FFF345EFBAD8</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-4</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pharmatics Limited</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pharmatics</gtr:description><gtr:id>C60F32D3-4FD0-4E74-8C04-4911804DAE2F</gtr:id><gtr:impact>Too early</gtr:impact><gtr:outcomeId>58c6728e2f0040.57917883-1</gtr:outcomeId><gtr:partnerContribution>Pharmatics will provide analytical services using machine learning techniques.</gtr:partnerContribution><gtr:piContribution>MATURA will provide samples from RA patients treated with biologics, samples from responders and non-responders will be analysed by Pharmatics using machine learning to identify candidate biomarkers.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AbbVie</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Abbvie</gtr:description><gtr:id>7C3DE83D-8847-4C04-BCFA-56E2DCB3198B</gtr:id><gtr:impact>Research collaboration has resulted in agreement to advance knowledge transfer and data sharing between partners.</gtr:impact><gtr:outcomeId>546497196880d0.18215888-1</gtr:outcomeId><gtr:partnerContribution>Research collaboration has resulted in agreement to advance knowledge transfer and data sharing between partners.</gtr:partnerContribution><gtr:piContribution>Research collaboration has resulted in agreement to advance knowledge transfer and data sharing between partners.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MATURA Consortium</gtr:description><gtr:id>0ADD92DD-C462-459A-BF56-85B3B18346E2</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-10</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pfizer</gtr:description><gtr:id>01D1719B-F3CF-41A0-B10D-5363CA14FF94</gtr:id><gtr:impact>Full support in providing STRAP clinical trial IMP Etanercept.</gtr:impact><gtr:outcomeId>54648dd5052e47.76327672-1</gtr:outcomeId><gtr:partnerContribution>We are running the research study and sharing data.</gtr:partnerContribution><gtr:piContribution>Research collaboration and data sharing. The collaboration will enable the proposed study to be undertaken by providing drug that will
allow for comparison of response within the proposed subsets of rheumatoid arthritis. In addition, the collaboration between the consortium and industry in the design of the trial will lead to an optimized study protocol. Lastly, analysis of the
samples will enable exploratory biomarker research to identify new, non-invasive, biomarkers and potential companion diagnostics.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Beijing Genomics Institute</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>BGI Tech Solutions (Hong Kong)</gtr:description><gtr:id>54DA74D5-0EA9-4614-9D99-5B69A00F88E0</gtr:id><gtr:impact>To facilitate research in this area the collaboration between industry and academia is required
to build an all encompassing network of UK clinical excellence. The desired output of this
research collaboration would generate a new approach to clinical practice with the
accelerated adoption of a personalised medicine for the benefit of patients and the national
healthcare budget</gtr:impact><gtr:outcomeId>54648acb96ae06.94814744-1</gtr:outcomeId><gtr:partnerContribution>Research collaboration whereby BGI provide next generation technology to analyse samples that could lead to potential companion diagnostics.</gtr:partnerContribution><gtr:piContribution>Data sharing and knowledge transfer.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MATURA Consortium</gtr:description><gtr:id>25404F96-F7DD-4756-A8F5-2DF9B96C8EEE</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-5</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>AZ Medimmune</gtr:department><gtr:description>Medimmune</gtr:description><gtr:id>067B8BE1-2682-4EE9-86BD-1EF806AB4065</gtr:id><gtr:impact>MedImmune are providing in kind support by providing intellectual input on using
microarrays, statistical analysis of large and complex data sets from clinical studies. In addition
MedImmune has an extensive history of antibody generation and biologics in diseases such as lupus, RA,
asthma and COPD and will use this knowledge to support the design and interpretation of data from the
consortium and to support the governance of the collaboration.</gtr:impact><gtr:outcomeId>5464936360f4e9.84972204-1</gtr:outcomeId><gtr:partnerContribution>Research collaboration knowledge transfer and data sharing.</gtr:partnerContribution><gtr:piContribution>Research collaboration knowledge transfer and data sharing.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MATURA Consortium</gtr:description><gtr:id>7C7A7469-82B1-4538-BC55-A8794BBD3095</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-2</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MATURA Consortium</gtr:description><gtr:id>CC82B1AD-9CCA-4838-9A8A-B639AE12F839</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-7</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Qiagen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Qiagen</gtr:description><gtr:id>80265E31-1262-4C04-BD9B-E824014A62CB</gtr:id><gtr:impact>The contribution of QIAGEN will be the training and transfer of know-how in
the product development of molecular diagnostics to the required technical, regulatory and
quality standards necessary for transfer for verification and manufacturing of a diagnostic
product.</gtr:impact><gtr:outcomeId>54648f5da0bce9.35760547-1</gtr:outcomeId><gtr:partnerContribution>Have given support in developing a more accurate understanding of the mechanisms driving RA to inform clinically
relevant developments of diagnostic algorithms and stratifiy patients to the most appropriate
therapy.
Have given support in developing molecular assays which could be used for investigational purposes within the
MATURA collaboration. On selection and verification of the appropriate biomarkers and with
supporting clinical evidence generated through the MATURA infrastructure, resources and
patient cohorts QIAGEN Manchester may then initiate the development of diagnostic
products for immediate clinical utility. The diagnostics products could be prognostic for
classifying disease subtype and severity or predictive (companion diagnostics) for guiding
therapy selection and treatment of patients</gtr:partnerContribution><gtr:piContribution>Research collaboration has resulted in agreement to advance knowledge transfer and data sharing between partners.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MATURA Consortium</gtr:description><gtr:id>0322519F-8A35-4A64-8872-AAE127B332A1</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-8</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Janssen Research &amp; Development</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Janssen</gtr:description><gtr:id>4E356E38-4B2F-473F-A1B2-D4EE59CD52E8</gtr:id><gtr:impact>Janssen have already provided expertise and will potentially provide prior data to support specific hypothesis testing in MATURA. They have agreed access to unique patient populations for replication and validation of results from MATURA. They have also contributed knowledge and expertise in informatics and use of the TranSMART knowlege Management Platform.</gtr:impact><gtr:outcomeId>546494a3054b10.59649405-1</gtr:outcomeId><gtr:partnerContribution>The main objective of this collaboration is for both industry and academic parties to engage
in order to:
1. Develop a more accurate understanding of the mechanisms driving RA to inform clinically
relevant developments of diagnostic algorithms and stratifiy patients to the most appropriate
therapy.
2. Join the MATURA Research/Discovery Programme by contributing: a) expertise in analysis
of RA genetic and genomic datasets b) access to replication cohorts for independent
validation of primary results
3. Develop a companion diagnostic, based on the emerging of few cellular / molecular
biomarkers that could be encompassed in a relatively simple test.
4. Potentially capitalise on the MATURA Consortium infrastructure to develop novel
compounds which would benefit from disease tissue target validation.</gtr:partnerContribution><gtr:piContribution>The main objective of this collaboration is for both industry and academic parties to engage
in order to:
1. Develop a more accurate understanding of the mechanisms driving RA to inform clinically
relevant developments of diagnostic algorithms and stratifiy patients to the most appropriate
therapy.
2. Join the MATURA Research/Discovery Programme by contributing: a) expertise in analysis
of RA genetic and genomic datasets b) access to replication cohorts for independent
validation of primary results
3. Develop a companion diagnostic, based on the emerging of few cellular / molecular
biomarkers that could be encompassed in a relatively simple test.
4. Potentially capitalise on the MATURA Consortium infrastructure to develop novel
compounds which would benefit from disease tissue target validation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PEAC Genotypic analysis of Methotrexate responsiveness</gtr:description><gtr:id>FA060258-3698-42B7-B1D5-6D374D2DEE98</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e157cee92614.06108538-1</gtr:outcomeId><gtr:partnerContribution>Genetic analysis including methylation studies</gtr:partnerContribution><gtr:piContribution>Provided DNA samples from MTX responders and non-responders for analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Protagen AG</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Protagen</gtr:description><gtr:id>66A136BC-7941-451D-88B8-4867FA469577</gtr:id><gtr:impact>work ongoing</gtr:impact><gtr:outcomeId>56e0552a9910c7.21993515-1</gtr:outcomeId><gtr:partnerContribution>Analysis of Autoantibodies as Biomarkers for RA Treatment Response To Biological Drugs and MTX in Samples from the MATURA through making the SeroTag-technology available for the detection of initially 400 autoantibodies in biological fluid of RA patients.</gtr:partnerContribution><gtr:piContribution>Thoroughly characterized samples with well documented clinical and laboratory data will be provided by the MATURA-consortium
It is planned, that the MATURA consortium will provide the required number of samples for a statistical significant result.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Avacta Group</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Avacta</gtr:description><gtr:id>1E371523-9FE0-455E-9D0C-6EA7E059C525</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05130e37a85.01591735-1</gtr:outcomeId><gtr:partnerContribution>Avacta will provide analytical services and reagents for the analyses.</gtr:partnerContribution><gtr:piContribution>MATURA will provide samples from RA patients treated with biologics, samples from responders and non-responders will be analysed by Avacta using their Affirmer Arrays to identify candidate biomarkers.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Medicine</gtr:department><gtr:description>MATURA Consortium</gtr:description><gtr:id>521E6BD9-41D1-4EF7-931F-69B835970693</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>56e05d9b090613.41079049-1</gtr:outcomeId><gtr:partnerContribution>All partners contribute to Project Steering Group meetings (quarterly) and the annual scientific meeting.

WS1 partners are actively recruiting patients to the STRAP trial. 

WS2 partners are providing clinical samples, data and are involved in the analysis.</gtr:partnerContribution><gtr:piContribution>The collaboration is led and coordinated by Professor Pitzalis in London and Prof Barton in Manchester. There are 2 Work Streams. QMUL lead and contribute to WS1. 

WS1 will analyse synovial markers in the PEAC dataset (http://www.peac-mrc.mds.qmul.ac.uk) and run the prospective randomised clinical trial, STRAP, to test the hypothesis that discrete cellular and molecular signatures in the synovial tissue (pathotypes) can be utilized to predict the response to existing biological therapies.

We will evaluate whether stratification of patients according to their synovial B cell infiltrate (poor or rich phenotypes) will better define response rates. We hypothesise that the Tocilizumab and Etanercept are superior to Rituximab in B-cell-poor patients. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy 

Work Stream 2 - has already collected blood samples and clinical information from large groups of patients treated with each of the 4 drugs we are focussing on (data on 3,000 anti-TNF, 1500 MTX 800 RTX and 200 TOC treated patients). We have followed these patients up from them starting the drug to 12 months later and, along the way, have collected blood samples, clinical information and data about the effectiveness and/or side effects of the drugs. This provides a wonderful starting point to test genetic variants, proteins and other molecules to find a set of biomarkers that together can be used to select the treatment most likely to work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Stratified Medicine Engagement Event - Leeds</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>652DB94A-B13F-4768-9C87-032C1D5FC72F</gtr:id><gtr:impact>Patient engagement event to increase awareness of the potential for stratified medicines in the treatment of rheumatoid arthritis. 
Presentations on the general principles and research studies ongoing in the local area were followed by discussions initiated by the audience.</gtr:impact><gtr:outcomeId>58bee5c9950898.75041635</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STRAP Newsletters</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E52447F1-EB81-4D4D-BC3B-C0B9A8C230D3</gtr:id><gtr:impact>Monthly newsletter to inform staff at participating hospitals and industry partners of current progress, upcoming meetings, best practice and an overview of updates to study documentation.</gtr:impact><gtr:outcomeId>56e04a99b589e4.47652161</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stratification of Therapy for RA by Pathobiology (STRAP) website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2B65F535-3CB3-44DB-ABB5-D59D38D0C052</gtr:id><gtr:impact>The STRAP website provides provides information to the public, patients and professionals on:
The study objectives
The study investigators and core team
Study overview - including the visit schedule 
Participating hospitals
Recruitment updates




Research investigators have a common central platform from which to gain new information and new research nurses have looked at the site to learn about the study. Please see: http://www.matura-mrc.whri.qmul.ac.uk/</gtr:impact><gtr:outcomeId>54623d119c7a54.28247162</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.matura-mrc.whri.qmul.ac.uk/</gtr:url><gtr:year>2014,2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stratified Medicine Engagement Event - Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A998A4D7-23DA-4EB3-BE9B-61BB62DD7121</gtr:id><gtr:impact>Patient engagement event to increase awareness of the potential for stratified medicines in the treatment of rheumatoid arthritis. 
Presentations on the general principles and research studies ongoing in the local area were followed by discussions initiated by the audience.</gtr:impact><gtr:outcomeId>58bee66f9528a7.65877026</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stratified Medicine Engagement Event - Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5FB0CD2A-8C4F-4E50-9B37-F128C30EBCA3</gtr:id><gtr:impact>Patient engagement event to increase awareness of the potential for stratified medicines in the treatment of rheumatoid arthritis. 
Presentations on the general principles and research studies ongoing in the local area were followed by discussions initiated by the audience.</gtr:impact><gtr:outcomeId>58bee6db8c3972.02218597</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC RA-MAP CMB and PSG Meetings London 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>736F83EB-A2B5-4362-8140-8470BE562A45</gtr:id><gtr:impact>Strategic planning around future research directed at predictors of remission in RA.</gtr:impact><gtr:outcomeId>58be8eab04cf41.13095355</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STRAP posters</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>24CA7FC2-A17F-470C-9F5B-4D5BA9E2976C</gtr:id><gtr:impact>Posters were designed and printed for display in rheumatology clinics where the STRAP study is recruiting patients. The design is also used on display screens in clinics.</gtr:impact><gtr:outcomeId>58bee910b05ef7.76186874</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Appointment of Lay Chair to the MATURA Patient Advisory Group and regular meetings with Lay Chair</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2BCC672F-0959-446E-88B7-DDC4E8AC4CDE</gtr:id><gtr:impact>Review of STRAP patient information documents by Lay Chair. Development of strategy for MPAG and organisation of the group as well as sourcing members using the Chair's links with other patient organisations.


Amendments and changes were made to documents which have been implemented.</gtr:impact><gtr:outcomeId>54623e930f5b58.59212290</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MATURA Patient Advisory Group presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>53022814-B6A5-4D0F-92A4-A1DF8FBE913B</gtr:id><gtr:impact>Findings from work carried out in MATURA relating to blood biomarkers to predict response to therapy in patients with rheumatoid arthritis were presented, generating considerable discussion. Specifically, the group were asked to comment on planned questions for a discrete choice experiment and made valuable suggestions.</gtr:impact><gtr:outcomeId>58bfc586e3ef34.49549738</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Precision Medicine UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1C4B945B-B86C-40F0-BBE7-ED0B5ECB54E9</gtr:id><gtr:impact>NOCRI joined UK leaders in the research, development and commercialisation of precision medicine for a one-day event this week designed to encourage new partnerships and highlight new opportunities in the field. The Precision Medicine UK: Collaboration Nation event at De Vere Holborn Bars, London, on 9 December was organised on behalf of the Stratified Medicine Innovation Platform by Innovate UK,, National Institute for Health Research, Cancer Research UK,Medical Research Council, Invest Northern Ireland, Health and Care Research Wales and the Knowledge Transfer Network, with the NIHR Office for Clinical Research Infrastructure (NOCRI) coordinating the NIHR's involvement. The day formed part of a programme to make the UK a world leader in precision medicine and provided real-world examples of the discovery and development of precision medicine solutions, through talks, panel discussions, workshops and exhibitions with the opportunity to arrange one-to-one partnering meetings. Precision medicine is an emerging approach to the treatment and diagnosis of disease that takes into account variations in a patient's genes, environment and lifestyle. It aims to better target treatments to an individual's circumstances to improve outcomes for patients. Representatives from across the NIHR were involved in the day and presented on a range of projects and funding programmes. Professor Bryan Williams of NIHR UCLH Biomedical Research Centre joined the first panel of the day which highlighted UK investments in the invention and evaluation phase of research. Professor Williams' highlighted key NIHR's investments in this space and provided examples of exciting precision medicine projects from UCLH BRC. In addition, a number of NIHR precision medicine projects were presented during the disease area specific showcase sessions. This included Professor Costantino Pitzalis who presented the THERAPIST study on behalf of the NIHR Translational Research Partnership, Professor Simon Mead's who presented a project at NIHR Queen's Square Biomedical Research Unit on the &amp;quot;dementia chip&amp;quot; and Professor Tariq Sadiq's who presented on Capacity Building and Delivery of Precision Medicine in Sexual Health, through NIHR Funding. Mark Samuels, Managing Director of NOCRI, also chaired a discussion panel themed 'Enabling Collaboration', which highlighted the value of collaborative working between companies, academics, charities and patients. The event saw the launch by the chief executive of Innovate UK, Dr Ruth McKernan, of a new map of the precision medicine landscape. A whole range of organisations, including charities, health bodies and devolved administrations are coordinating their work under the umbrella of Innovate UK's Stratified Medicine Innovation Platform, with NOCRI representing the NIHR.</gtr:impact><gtr:outcomeId>56e16d5a4486a5.17697480</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stratified Medicine Engagement Event - Newcastle</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8D577053-754B-4E6E-A184-E77D01D08D48</gtr:id><gtr:impact>Patient engagement event to increase awareness of the potential for stratified medicines in the treatment of rheumatoid arthritis. 
Presentations on the general principles and research studies ongoing in the local area were followed by discussions initiated by the audience.</gtr:impact><gtr:outcomeId>58bee7439760b5.48340295</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MATURA Patient Advisory Group (MPAG), meeting 10th December</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6F9B625A-28CF-4F53-80F3-03C5052E2A22</gtr:id><gtr:impact>to be updated after event</gtr:impact><gtr:outcomeId>5462408fdcf4f7.24737724</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.matura.whri.qmul.ac.uk/what_is_matura.php</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MATURA Public Launch Symposium</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>94DBC26F-B412-4205-B146-5DF8B44D1139</gtr:id><gtr:impact>Increased awareness of the programme 
Potential collaborators, academic and commercial, identified.

To be updated after event</gtr:impact><gtr:outcomeId>5462400e34bba6.12209140</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.matura.whri.qmul.ac.uk/files/News/MATURA_Public_Launch_Symposium_090115.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stratified Medicine Leaflets</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AC1D8ACD-98BE-4F33-B1F0-1ECB3D60CDCE</gtr:id><gtr:impact>A leaflet was designed and printed for distribution at patient events e.g. NRAS meetings and at hospital clinics to increase the understanding and awareness of the potential for stratified medicines in the treatment of rheumatoid arthritis.</gtr:impact><gtr:outcomeId>58bee856b4ae32.77076434</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Queen Mary Trial Advisory Group (QMTAG) review of STRAP patient information documents</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D0D65AC6-F937-4920-A7E6-6120C0D607F0</gtr:id><gtr:impact>Review of STRAP patient information documents by patient group.




Documents were discussed and suggestions for changes made to patient information.
Amendments and changes to patient documents have been implemented.</gtr:impact><gtr:outcomeId>54623f87acdf30.32141834</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>&quot;Bones&quot; Exhibition at the Great North Museum 2017</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C4B579E6-036B-458F-8814-065259C72E0B</gtr:id><gtr:impact>Workshops, demonstrations, talk, events and public information materials presented in parallel with the Bones Exhibition at the Great North Museum highlighting musculoskeletal research at our Centres of Excellence at Newcastle University including the Centre for Integrated Musculoskeletal Ageing, the Newcastle Experimental Arthritis Treatment Centre, the Rheumatoid Arthritis Centre of Excellence and the Newcastle Biomedical Research Centre.</gtr:impact><gtr:outcomeId>58bd5398c9bac6.09099676</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://greatnorthmuseum.org.uk/whats-on/bones-skeleton-secrets-of-the-animal-world</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MATURA Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B4CBAB66-16FE-4F9C-AC01-8C444533F061</gtr:id><gtr:impact>The MATURA website provides information to the public, patients and professionals on the consortium's members, objectives and research projects. News items are regularly added and the site has a PPI page which has been designed and written by patients. Potential partners, both academic and commercial, can access the process for joining/requesting samples and the relevant application forms.

For consortium members there is a secure document repository area.</gtr:impact><gtr:outcomeId>56e043f6ce7677.47789453</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.matura.whri.qmul.ac.uk</gtr:url><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STRAP eligibility cards</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B11AA673-D59F-4482-A682-E45E53B53007</gtr:id><gtr:impact>Credit cards were designed and printed to remind practitioners of the eligibility criteria for patients to participate in the STRAP trial. The cards are worn on lanyards.</gtr:impact><gtr:outcomeId>58bee9d33b5ca2.30085038</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MATURA Scientific Symposium</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AA7FD8A3-A594-490C-86C5-C5D4D3E27830</gtr:id><gtr:impact>MATURA consortium partners, academic and commercial, presented on current progress with projects to:
1. Share information
2. Identify further areas for collaboration best practice
3. Obtain feedback from the Scientific Advisory Panel (SAB)
Outcomes included:
1.In-depth informed discussion 
2. Identification of sharing procedures across international consortia
3. Ideas for future research 
4. A positive feedback report from the SAB</gtr:impact><gtr:outcomeId>56e03e9e8cd148.07293543</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MPAG Patient Group Meetings</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EAE5054E-6820-4F6D-8F68-AA4537B71521</gtr:id><gtr:impact>To involve and engage RA patients in the stratified medicine research programme</gtr:impact><gtr:outcomeId>56e0343b3469e8.63940690</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.matura.whri.qmul.ac.uk/what_is_matura.php</gtr:url><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MATURA Operational</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>700AE792-07D3-4E37-A138-027E922FEDAC</gtr:id><gtr:impact>Monthly teleconferences of the STRAP (WS1) and Biostats (WS2) teams. 
Quarterly Project Steering Groups
Bi-annual Consortium Management Board meetings
Annual Scientific Conference</gtr:impact><gtr:outcomeId>56e186fce6db96.47605826</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2015,2016,2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>12000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK- Special Strategic Award</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>20670</gtr:fundingRef><gtr:id>AB7D40B1-B16F-49D8-B274-7109C1FCEF8A</gtr:id><gtr:outcomeId>58bed295b2bed0.83500681</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR Manchester BRC</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>9F72D503-DE8B-454C-8261-CC6378CFBBD0</gtr:id><gtr:outcomeId>58bfcf967348b9.19476052</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC equipment</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>628B9A93-E71C-4BFB-989C-D6A5AE0AB5A8</gtr:id><gtr:outcomeId>58c675478577e2.64692610</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Translational Research Collaboration for Joint &amp;amp; related inflammatory diseases- Steering Committee Meeting</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EE65872E-A778-4AD8-9A4D-30F21D2D0C7C</gtr:id><gtr:outcomeId>58c1744c6dc8f3.13809787</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/collaborations-for-early-phase-translational-research/collaborate-with-our-experts-translational-research-partnerships/joint-and-related-inflammatory-diseases-translational-research-partnership.htm</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ACR/eular Exchange Program</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>7491EF5D-A1E8-433C-B3AD-D5F2B9842566</gtr:id><gtr:outcomeId>58c185859492c0.14992883</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Addressing the grand challenges in Immune Mediated Inflammatory Diseases</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>52848210-9A33-47A6-9A32-EDCB1C964A6E</gtr:id><gtr:outcomeId>58c175c138d1a9.17312043</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Joint NIHR CRN/UK Pharmacogenetics &amp;amp; Stratified Medicine Network Workshop. A Roadmap for Delivery of Stratified Medicine Research within the NHS (Nov 16)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6D248D6D-27AC-4318-B5EB-C6FD941E3379</gtr:id><gtr:outcomeId>58c17c0c170173.71669285</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Arthritis Research UK Rare Diseases Workshop 2017</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>18BF5426-8C5E-42CE-943D-5FE9E5E4D8BF</gtr:id><gtr:outcomeId>58bd5ae00fc3f9.12459038</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EULAR Synovitis Study Group</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>2AF34890-0C0A-416C-A666-84A3863527C3</gtr:id><gtr:outcomeId>58c188242725b6.38649619</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.eular.org/investigative_rheumatology_study_groups.cfm</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Newcastle Audit Meeting</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>329A28D4-6E35-486E-AC80-CF52F71AB569</gtr:id><gtr:outcomeId>58bd5fbe096308.22182536</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Training in Disease Activity Scores &amp;amp; Ultrasound Assessments of RA</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D025FE98-647C-4DF1-8A9B-CFD2EB3E709E</gtr:id><gtr:impact>Greater consistency in evaluating and recording of measures of disease in RA</gtr:impact><gtr:outcomeId>56e0490a9b07e6.96886727</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence on Funding Policy: MRC, NIHR, ARUK recognised need to fund Stratified Medicine Programmes in RA. PEAC has formed the platform for a suite of stratified Medicine programmes including MATURA and R4RA</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B8DB0502-1EB3-46FC-80B6-493D229DC061</gtr:id><gtr:outcomeId>56e16e894b5403.56338667</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>AMP RA SLE Steering Committee</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>3E55129F-4C3D-4A7F-A5B2-93E86F740EFA</gtr:id><gtr:outcomeId>58c178e9dfcfd2.33102832</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>https://www.nih.gov/research-training/accelerating-medicines-partnership-amp</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Development of immune tolerance therapies for the treatment of rheumatic diseases - THE INNOVATIVE MEDICINES INITIATIVE</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>2D89FF41-1835-4C21-9C14-AC83CA978D74</gtr:id><gtr:outcomeId>58c1778ccc0684.53406850</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.imi.europa.eu</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Annual EATC/EOTC Directors Meeting - Arthritis Research UK</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7C7512DE-A522-46B5-9C56-7E2406E2D258</gtr:id><gtr:outcomeId>58c1301578ac63.01524215</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Ultrasound Guided Synovial Biopsy Courses</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>D3AF5FF9-4D6A-4E6F-80AE-5508408D6A0C</gtr:id><gtr:outcomeId>56e0484fb15c85.88492210</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.matura-mrc.whri.qmul.ac.uk/ultrasound_guided_synovial_biopsy_taking_a_biopsy.php</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC Population and Systems Medicine Board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F2CB49D1-D7DA-4AAA-A081-86CFC1AFA57E</gtr:id><gtr:outcomeId>58bd5f526aff29.67780671</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>This study will aim to test the utility of synovial histopathology and cell type as a potential biomarker to guide therapeutic decisions in RA patients failing DMARD therapy and started on Rituximab, Tocilizumab or Etanercept therapy. 
Specifically, can a diagnostic synovial biopsy showing a B-cell &amp;quot;rich/poor pathotype&amp;quot; define specific disease responsive/resistant subsets for patient stratification and help rationalise biologic drug choice? 
The trial is currently under review by the REC and MHRA and is jointly funded by the MRC and ARUK.</gtr:description><gtr:id>5F2C95E5-C930-4023-A258-83A5A2B86ADE</gtr:id><gtr:impact>The aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential response to therapy. The following are notable impacts arising from trial development:

1. STRAP Protocol complete and patient related documents review by Queen Mary patient advisory group.
3. Clinical Database: testing underway.
4. REC and MHRA submitted. REC meeting 13th Nov 5. 
5. TMG formed and convenes frequently TSC will be in line with timelines. 
6. STRAP website launched.
7. Investigators Meeting 17th September 2014.</gtr:impact><gtr:outcomeId>5464c19b56eba3.71581742</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Stratification of Therapy for Rheumatoid Arthritis by Pathobiology (STRAP) Clinical Trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.matura-mrc.whri.qmul.ac.uk</gtr:url><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The TranSMART platform, which was originally developed and open sourced by our industrial partner, Janssen, is now widely used internationally for translational research (http://transmartfoundation.org/). The MRC-MATURA TranSMART has itself been developed in close collaboration with the MRC-PSORT and the MRC-RA-MAP consortium in collaboration with the Innovative Medicines Initiative (IMI) project European Translational Information and Knowledge Management Services (eTRIKS).The MRC-MATURA TranSMART is a web-based knowledge management platform that enables MATURA consortium members to develop and refine research hypotheses by investigating correlations between genetic, genomic and phenotypic data, and assessing their analytical results in the context of published literature and other work related to RA disease pathology and drug response.</gtr:description><gtr:id>47DA303C-0D63-4F27-BBE1-078FCB95F826</gtr:id><gtr:impact>The MRC-MATURA TranSMART infrastructure enables inte&amp;shy;&amp;shy;grated analysis towards the identification of biomarker signatures that will help researchers and clinicians better understand the different responses to biologic drugs that are seen in the clinic, ultimately offering better and more personalised treatment to those affected by rheumatoid arthritis.
The MRC-MATURA TranSMART platform enables researchers to:

Develop, test and refine research hypotheses
Search multiple data sets for potential drug targets, pathways and biomarkers
Compare data from proteomics, metabolomics and other &amp;quot;omics&amp;quot; studies
Contrast patterns of gene expression in healthy and diseased individuals and tissue samples
Investigate correlations between genotype and phenotype in clinical trial data
Study genetic and environmental factors involved in RA
Display data visually using a graphical interface
Stratify clinical data into molecular subtypes of RA disease and drug response
Collaborate across the academic and industrial partnership of the MATURA consortium</gtr:impact><gtr:outcomeId>54624157327372.63061778</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>TranSMART</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Study specific Electronic Data Capture (EDC) system for STRAP. This includes a electronic Case Record Form (eCRF) as well as a Study Management system linking clinical data to pathobiology data. The EDC system is designed to follow the order of the study assessments and include all the clinical data (incl. Medication history, lifestyle factors questionnaire, DAS28 etc). submission to the database is via an encrypted and password protected link dedicated to each individual centre. This database is designed to provide an online facility to monitor registration, transport and processing of STRAP samples, from the clinic to the microscope.</gtr:description><gtr:id>9250E4DC-4315-4604-AD54-72CD605243EF</gtr:id><gtr:impact>Management of the study 
High quality research data</gtr:impact><gtr:outcomeId>56e186498a97f6.75756941</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>STRAP study database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://www.matura-strap-mrc.whri.qmul.ac.uk</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>EMR biobank containing over 800 synovial biopsies supports multiple projects and each research project adds to the samples and information available 

Synovial biopsies are linked to tight clinical databases including ultrasound synovitis assessments</gtr:description><gtr:id>01F97FE0-7FDB-45F6-9DCB-3C6C165047E6</gtr:id><gtr:impact>Supports academic and industry collaborations</gtr:impact><gtr:outcomeId>56e191049df984.01117883</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>EMR Biobank</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0FF7FA86-241F-400C-A300-0F5FBE18CC08</gtr:id><gtr:title>GeneImp: Fast Imputation to Large Reference Panels Using Genotype Likelihoods from Ultralow Coverage Sequencing.</gtr:title><gtr:parentPublicationTitle>Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a47c0cfdb605f07ed40e6050e2560dd"><gtr:id>6a47c0cfdb605f07ed40e6050e2560dd</gtr:id><gtr:otherNames>Spiliopoulou A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0016-6731</gtr:issn><gtr:outcomeId>5a93f4c92f9c66.93962860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A099C67-D81C-433C-9F96-E03BFC6F8663</gtr:id><gtr:title>DNA methylation as a marker of response in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7679670ecc1c50de0878ecfe579eea5"><gtr:id>d7679670ecc1c50de0878ecfe579eea5</gtr:id><gtr:otherNames>Nair N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>5a8bee8750fc73.68661072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C93A0634-A817-4FE7-AD2C-C80A148B2721</gtr:id><gtr:title>Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study.</gtr:title><gtr:parentPublicationTitle>BMC musculoskeletal disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85f703b15dc07402323748f3f2d9d163"><gtr:id>85f703b15dc07402323748f3f2d9d163</gtr:id><gtr:otherNames>Kumar K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2474</gtr:issn><gtr:outcomeId>58b94799c969d0.62784894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58A4070C-FB90-41D7-A14B-BC873ED8A8A5</gtr:id><gtr:title>Peripheral and synovial mechanisms of humoral autoimmunity in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fc9cdf05dee98ba5676331d9b39a2fd"><gtr:id>9fc9cdf05dee98ba5676331d9b39a2fd</gtr:id><gtr:otherNames>Corsiero E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>54609445e1ca27.84577203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EFFCB10-3974-4AAA-8581-9BBEE1F04161</gtr:id><gtr:title>A multi centre retrospective analysis evaluating performance of synovial biopsy techniques: arthroscopic vs. ultrasound guided vs. blind needle biopsy.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e207d7f627ccf2bca8964f0049ea4196"><gtr:id>e207d7f627ccf2bca8964f0049ea4196</gtr:id><gtr:otherNames>Humby F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5a96d978749ef6.67922923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9166B12-39E1-4779-9C1F-2B15F45F5FC4</gtr:id><gtr:title>Ectopic lymphoid neogenesis in rheumatic autoimmune diseases.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be82894edbca58453cb3f244f0a28171"><gtr:id>be82894edbca58453cb3f244f0a28171</gtr:id><gtr:otherNames>Bombardieri M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>58b957b385ef83.56972166</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62D04F2A-38D6-40F5-B5C6-CA1E9AE52FCE</gtr:id><gtr:title>Stratified medicine in rheumatoid arthritis-the MATURA programme.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/796926032895f22b62c49cf3d20969f9"><gtr:id>796926032895f22b62c49cf3d20969f9</gtr:id><gtr:otherNames>Barton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>58b957b35bc2e4.99808412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A60A0539-B8AD-436B-AF95-C613AC5FBBF8</gtr:id><gtr:title>Sample size requirements for learning to classify with high-dimensional biomarker panels.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/553c0e37965ca74d78a27c05b41c3450"><gtr:id>553c0e37965ca74d78a27c05b41c3450</gtr:id><gtr:otherNames>McKeigue P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>5a93f4c8be2893.18649676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECA28172-3535-4F03-A7B3-C348CE262275</gtr:id><gtr:title>Synovial tissue research: a state-of-the-art review.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c97c2eb4a414045387ec4115ba3ed310"><gtr:id>c97c2eb4a414045387ec4115ba3ed310</gtr:id><gtr:otherNames>Orr C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>5a96d976a55c36.04372365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84B82E47-7969-437C-9387-1EA2812CD8ED</gtr:id><gtr:title>The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f030fc21ac0909c22d58b7558f2701"><gtr:id>e7f030fc21ac0909c22d58b7558f2701</gtr:id><gtr:otherNames>Smith SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a9d15edc99d75.23075383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03C99E51-4313-4C63-ACC7-1E7AA2E61364</gtr:id><gtr:title>Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register.</gtr:title><gtr:parentPublicationTitle>The Journal of rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a3092ac865f7e1a0a0a0ef6c9d4c86d"><gtr:id>1a3092ac865f7e1a0a0a0ef6c9d4c86d</gtr:id><gtr:otherNames>Twigg S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0315-162X</gtr:issn><gtr:outcomeId>5a9943ea2dfbf1.10735298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4946FFAF-D40C-4A42-80A0-C0C58518BF6E</gtr:id><gtr:title>Identifying Causal Genes at the Multiple Sclerosis Associated Region 6q23 Using Capture Hi-C.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d3f72913971.35357099</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62A55D61-403F-4EF9-B458-D07AB762670A</gtr:id><gtr:title>Affimer proteins inhibit immune complex binding to Fc?RIIIa with high specificity through competitive and allosteric modes of action.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40b1b4d714ec05126f83b168ee523b09"><gtr:id>40b1b4d714ec05126f83b168ee523b09</gtr:id><gtr:otherNames>Robinson JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5a969440e4eeb6.39370982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46062BF2-1C37-49BB-9777-3D09892A9F3A</gtr:id><gtr:title>MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6034b3f3e7c6b7a1167bd45177ae553"><gtr:id>c6034b3f3e7c6b7a1167bd45177ae553</gtr:id><gtr:otherNames>Morgan MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>5a9d169287ed96.50648248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB601055-2311-44C9-BECB-C9869D5F11CE</gtr:id><gtr:title>MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93f8556619f3487d06c35513ec7d86fb"><gtr:id>93f8556619f3487d06c35513ec7d86fb</gtr:id><gtr:otherNames>Li X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a93f4c90408c7.88133996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D6794C5-6C1E-47FE-BD09-5CE4DA27EE83</gtr:id><gtr:title>Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f030fc21ac0909c22d58b7558f2701"><gtr:id>e7f030fc21ac0909c22d58b7558f2701</gtr:id><gtr:otherNames>Smith SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>585d70831b6720.70866662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CF746DB-B1A1-4A04-8B0F-F46509B7B2F7</gtr:id><gtr:title>Corrigendum: Synovial tissue research: a state-of-the-art review.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c97c2eb4a414045387ec4115ba3ed310"><gtr:id>c97c2eb4a414045387ec4115ba3ed310</gtr:id><gtr:otherNames>Orr C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>5a96d977ea4e12.26114280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30F5E843-85E1-4E61-8970-576AB33DDA17</gtr:id><gtr:title>Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b3441493f8ea501dd2f642269d610b3"><gtr:id>0b3441493f8ea501dd2f642269d610b3</gtr:id><gtr:otherNames>Nikiphorou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a9d1621906b84.95821056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E4D6E53-D9D4-4FDC-BC88-507C13378CE9</gtr:id><gtr:title>Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23a15d47d75991935df7dc66c4915c95"><gtr:id>23a15d47d75991935df7dc66c4915c95</gtr:id><gtr:otherNames>Bissell LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a9d1657d2bc89.94689349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA35AE77-DFAE-4E9C-9204-08E711D28354</gtr:id><gtr:title>The Relationship Between Synovial Pathobiology and Magnetic Resonance Imaging Abnormalities in Rheumatoid Arthritis: A Systematic Review.</gtr:title><gtr:parentPublicationTitle>The Journal of rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e207d7f627ccf2bca8964f0049ea4196"><gtr:id>e207d7f627ccf2bca8964f0049ea4196</gtr:id><gtr:otherNames>Humby F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0315-162X</gtr:issn><gtr:outcomeId>5a96d976eef689.80303684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>105E17E8-2A3D-4DF3-AA9E-1F9907D7D3EC</gtr:id><gtr:title>Genetics of rheumatoid arthritis susceptibility, severity, and treatment response.</gtr:title><gtr:parentPublicationTitle>Seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5304a36e6749666aa259e801d7dbe8d"><gtr:id>b5304a36e6749666aa259e801d7dbe8d</gtr:id><gtr:otherNames>Viatte S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1863-2297</gtr:issn><gtr:outcomeId>5a2fd357d91d00.61362780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDE69585-70B5-422E-B2A6-FB1461A15972</gtr:id><gtr:title>Ectopic Lymphoid Structures: Powerhouse of Autoimmunity.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fc9cdf05dee98ba5676331d9b39a2fd"><gtr:id>9fc9cdf05dee98ba5676331d9b39a2fd</gtr:id><gtr:otherNames>Corsiero E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>58b9576e7a9165.08454192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DE0FCD3-E8FC-4856-9499-6D4C1E7438D7</gtr:id><gtr:title>OP0298 Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a34fb4eb7d870.18729448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>101EC342-8FD3-4D3F-92BE-3A4D8F7B7601</gtr:id><gtr:title>Synovial tissue research: a state-of-the-art review.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c97c2eb4a414045387ec4115ba3ed310"><gtr:id>c97c2eb4a414045387ec4115ba3ed310</gtr:id><gtr:otherNames>Orr C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>5a96d97781b4d8.18730768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4746B82-56D2-4075-8BCE-5EE82667CB26</gtr:id><gtr:title>Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa60081a1acdd014cb743285f5907ec3"><gtr:id>aa60081a1acdd014cb743285f5907ec3</gtr:id><gtr:otherNames>Mathews RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a9d16cce95705.38228415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>129B98E7-E403-4F45-A1FC-9F9D1524A6F4</gtr:id><gtr:title>CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene Identification.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f80410927098ba136af273f314e833b"><gtr:id>7f80410927098ba136af273f314e833b</gtr:id><gtr:otherNames>Thalayasingam N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5a995f879ed442.15033131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>926D795A-7C71-4818-BB35-B8F2295C975C</gtr:id><gtr:title>Transcriptional Profiling of Synovial Macrophages using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8ca364bf795aec6fc5163f309426c73"><gtr:id>a8ca364bf795aec6fc5163f309426c73</gtr:id><gtr:otherNames>Mandelin AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5a96d978bbbe37.00040568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E0AB360-C7DA-4078-8489-3F07BAE8A891</gtr:id><gtr:title>Can Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?</gtr:title><gtr:parentPublicationTitle>Frontiers in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bbc75fadca69f44d7e0178356db1f51"><gtr:id>7bbc75fadca69f44d7e0178356db1f51</gtr:id><gtr:otherNames>Humby FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2296-858X</gtr:issn><gtr:outcomeId>5a96d97643d9d5.08776158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8AAF98A-94B9-4F00-A75D-9B96DFC3FD2F</gtr:id><gtr:title>Is there a role of synovial biopsy in drug development?</gtr:title><gtr:parentPublicationTitle>BMC musculoskeletal disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4041a624c34e000ef45a2bda9280e8b4"><gtr:id>4041a624c34e000ef45a2bda9280e8b4</gtr:id><gtr:otherNames>Filkova M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2474</gtr:issn><gtr:outcomeId>58c7c84360bab4.28566674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B792FF7B-16C8-4867-9D7C-D461578A8275</gtr:id><gtr:title>Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements.</gtr:title><gtr:parentPublicationTitle>The Journal of rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e207d7f627ccf2bca8964f0049ea4196"><gtr:id>e207d7f627ccf2bca8964f0049ea4196</gtr:id><gtr:otherNames>Humby F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0315-162X</gtr:issn><gtr:outcomeId>56d5879b57fe63.93112791</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K015346/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>